Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Is randomisation of clinical trials still the gold standard?

Presentation of case/condition: Review of novel agents licensed for use in the 21st century


28 Sep 2019


Is randomisation of clinical trials still the gold standard?


Cytotoxic Therapy;  Bioethical Principles and GCP;  Immunotherapy;  Patient Education and Advocacy

Tumour Site


Udai Banerji


U. Banerji

Author affiliations

  • Drug Development Unit  , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.